InsiderTrades

Form 4 for GTBP GT Biopharma, Inc.

Accepted 2021-11-12 00:00:00 ET · period of report 2021-02-16 · accession 0001654954-21-012057 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2021-11-12 2021-02-25 GTBP Breen Michael Martin Dir C - Cnv Deriv $3.40 +50.1K 318.3K +19% +$170.3K
D 2021-11-12 2021-02-16 GTBP Breen Michael Martin Dir A - Grant $0.00 +278.1K 278.1K New $0
DM 2021-11-12 2021-02-25 GTBP Breen Michael Martin Dir C - Cnv Deriv $0.00 -130.0K 0 -100% $0
D 2021-11-12 2021-02-16 GTBP Breen Michael Martin Dir A - Grant $0.00 +50.0K 50.0K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-02-25 C A 9,859 $3.40 328,160 D — —
2 Common Common Stock 2021-02-16 A A 278,058 $0.00 278,058 D — — (F1) Represents a grant of shares of restricted stock ("RSAs"). 1/3rd of the RSAs vest on January 13, 2021, 2022 and 2023.
3 Common Common Stock 2021-02-25 C A 40,243 $3.40 318,301 D — —
4 Derivative 10% Senior Convertible Debenture 2021-02-25 C D 30,000 $0.00 0 D $3.40 · 2020-06-23 to 2021-06-23 9,859 Common Stock
5 Derivative 10% Senior Convertible Debenture 2021-02-25 C D 100,000 $0.00 0 D $3.40 · 2018-09-07 to — 40,243 Common Stock (F3) While the maturity date of the Debenture was September 7, 2019, the Registrant did not repay the Debenture on the maturity date and the Debenture remained outstanding until converted.
6 Derivative Option to purchase Common Stock 2021-02-16 A A 50,000 $0.00 50,000 D $6.33 · — to 2031-02-15 50,000 Common Stock (F2) 1/3rd of the shares vest on February 16, 2021, 2022 and 2023.